Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...

(Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

We recently published 10 Big Names Leading Wall Street Gains. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Sarepta Therapeutics (SRPT) surged after Mizuho upgraded to Outperform, citing strong Elevidys uptake and gene therapy ...

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...